NSC 14613
CAS No. 91396-88-2
NSC 14613( NSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid )
Catalog No. M16567 CAS No. 91396-88-2
PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 28 | In Stock |
|
| 10MG | 47 | In Stock |
|
| 25MG | 76 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | 228 | In Stock |
|
| 500MG | 383 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNSC 14613
-
NoteResearch use only, not for human use.
-
Brief DescriptionPluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
-
DescriptionPluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.
-
In VitroPluriSIn 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSIn 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSIn 1 treatment at 20 μM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSIn 1 treatment at 20 μM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSIn 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSIn 1. Moreover, treatment with PluriSIn 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSIn 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium.
-
In Vivo——
-
SynonymsNSC 14613 | N’-phenyl-hydrazine-Isonicotinic acid
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorSCD
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number91396-88-2
-
Formula Weight213.24
-
Molecular FormulaC12H11N3O
-
Purity>98% (HPLC)
-
SolubilityDMSO: 43 mg/mL (201.65 mM)
-
SMILESO=C(NNC1=CC=CC=C1)C2=CC=NC=C2
-
Chemical NameN'-phenylisonicotinohydrazide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ben-David U, et al. Cell Stem Cell, 2013, 12(2), 167-179.
molnova catalog
related products
-
IDH1-IN-1
Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
-
DHODH-IN-1
DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM.
-
BI-4916
BI-4916 is a selective phosphoglycerate dehydrogenase (PHGDH) inhibitor that inhibits SSP and reduces the migration of cancer cells.BI-4916 can be used in the study of cancer and metabolic diseases.
Cart
sales@molnova.com